Vitamin D deficiency adverse event reports that record this term

Kind of term: MedDRA preferred term
Plain meaning: low vitamin D

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From March 2004 to June 2026, FDA received 9,618 adverse event reports that record the MedDRA preferred term Vitamin D deficiency. In plain words, the term means: low vitamin D. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 542 reports in the 12 months to June 2026 and 525 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

Low vitamin D. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 101 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Vitamin D deficiency name as a suspect product, in order of name
Drug	Class	Reports with this term
Actemra	Interleukin-6 receptor antagonist	79
Actonel	Bisphosphonate	97
Adalimumab	Tumor necrosis factor blocker	35
Albuterol sulfate	beta2-Adrenergic agonist	25
Alendronate sodium	Bisphosphonate	540
Amlodipine	Calcium channel blocker	35
Amlodipine Besilate		37
Ampyra	Potassium channel blocker	62
Aredia		39
Asacol		63
Aspirin	Nonsteroidal anti-inflammatory drug	70
Atripla		671
Avonex	Interferon beta	69
Benadryl	Histamine-1 receptor antagonist	37
Boniva		151
Carbamazepine	Mood stabilizer	44
Carboplatin	Platinum-based drug	28
Cetirizine	Histamine-1 receptor antagonist	25
Cetirizine hydrochloride	Histamine-1 receptor antagonist	52
Cimzia	Tumor necrosis factor blocker	27
Clozapine	Atypical antipsychotic	26
Clozaril	Atypical antipsychotic	31
Complera	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	379
Cosentyx	Interleukin-17A antagonist	89
Crestor	HMG-CoA reductase inhibitor	72
Cyclophosphamide	Alkylating drug	37
Cyclosporine	Calcineurin inhibitor immunosuppressant	27
Cymbalta	Serotonin and norepinephrine reuptake inhibitor	61
Diclofenac	Nonsteroidal anti-inflammatory drug	29
Diphenhydramine hydrochloride	Histamine-1 receptor antagonist	39
Dupixent	Interleukin-4 receptor alpha antagonist	32
Enbrel	Tumor necrosis factor blocker	295
Ergocalciferol	Provitamin D2 compound	31
Esomeprazole	Proton pump inhibitor	44
Esomeprazole magnesium	Proton pump inhibitor	32
Esomeprazole Magnesium Naproxen		35
Finasteride	5-alpha reductase inhibitor	29
Forteo	Parathyroid hormone analog	92
Fosamax	Bisphosphonate	1,074
Fosamax Plus D		252
Furosemide	Loop diuretic	39
Gabapentin	Anti-epileptic agent	35
Gilenya	Sphingosine 1-phosphate receptor modulator	237
Gliclazide		45
Humira		469
Ibuprofen	Nonsteroidal anti-inflammatory drug	45
Infliximab	Tumor necrosis factor blocker	30
Januvia	Dipeptidyl peptidase 4 inhibitor	30
Keppra		25
Kisqali	Kinase inhibitor	58
Lamotrigine	Anti-epileptic agent	50
Lansoprazole	Proton pump inhibitor	33
Leflunomide	Antirheumatic agent	47
Letrozole	Aromatase inhibitor	35
Levetiracetam		54
Lipitor	HMG-CoA reductase inhibitor	30
Lisinopril	Angiotensin converting enzyme inhibitor	42
Losartan	Angiotensin 2 receptor blocker	29
Lyrica		107
Metformin	Biguanide	41
Methotrexate	Folate analog metabolic inhibitor	214
Methotrexate sodium	Folate analog metabolic inhibitor	38
Mirtazapine		29
Nexium	Proton pump inhibitor	429
NuvaRing	Estrogen	50
Ocrevus	CD20-directed cytolytic antibody	130
Olanzapine	Atypical antipsychotic	42
Omeprazole	Proton pump inhibitor	119
Orencia	Selective T cell costimulation modulator	73
Pantoprazole	Proton pump inhibitor	45
Plaquenil	Antimalarial	61
Prednisolone	Corticosteroid	47
Prednisone	Corticosteroid	149
Pregabalin		56
Prilosec	Proton pump inhibitor	126
Prilosec OTC	Proton pump inhibitor	42
Prolia	RANK ligand inhibitor	222
Propecia	5-alpha reductase inhibitor	70
Rebif	Interferon beta	63
Remicade	Tumor necrosis factor blocker	90
Revlimid	Thalidomide analog	47
Rituxan	CD20-directed cytolytic antibody	61
Rituximab	CD20-directed cytolytic antibody	130
Simponi	Tumor necrosis factor blocker	31
Stelara	Interleukin-12 antagonist	54
Stribild	Cytochrome P450 3A inhibitor	408
Symbicort	Corticosteroid	39
Tecfidera		80
Teduglutide	GLP-2 analog	35
Topiramate		46
Truvada	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	1,093
Tysabri	Integrin receptor antagonist	166
Vedolizumab	Integrin receptor antagonist	57
Viread	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	483
Xeljanz	Janus kinase inhibitor	81
Xgeva	RANK ligand inhibitor	31
Xolair	Anti-IgE	57
Xyrem	Central nervous system depressant	212
Xywav	Central nervous system depressant	32
Zometa		64
Zonisamide	Anti-epileptic agent	41

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 45 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Vitamin D deficiency name, in order of name
Class	Reports with this term
5-alpha reductase inhibitor	109
Angiotensin 2 receptor blocker	115
Angiotensin converting enzyme inhibitor	65
Anti-epileptic agent	234
Anti-IgE	79
Antimalarial	103
Antirheumatic agent	55
Aromatase inhibitor	70
Atypical antipsychotic	178
Benzodiazepine	82
beta-Adrenergic blocker	80
Biguanide	74
Bisphosphonate	1,763
Calcineurin inhibitor immunosuppressant	54
CD20-directed cytolytic antibody	352
Central nervous system depressant	246
Corticosteroid	323
Cytochrome P450 3A inhibitor	438
Estrogen	54
Folate analog metabolic inhibitor	252
GLP-1 receptor agonist	72
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	525
Histamine-1 receptor antagonist	191
HMG-CoA reductase inhibitor	144
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	1,480
Integrin receptor antagonist	244
Interferon beta	144
Interleukin-12 antagonist	67
Interleukin-17A antagonist	89
Interleukin-6 receptor antagonist	102
Janus kinase inhibitor	115
Kinase inhibitor	179
Mood stabilizer	79
Nonsteroidal anti-inflammatory drug	202
Opioid agonist	63
Parathyroid hormone analog	92
Potassium channel blocker	75
Proton pump inhibitor	923
RANK ligand inhibitor	271
Selective T cell costimulation modulator	88
Serotonin and norepinephrine reuptake inhibitor	106
Serotonin reuptake inhibitor	69
Sphingosine 1-phosphate receptor modulator	250
Thalidomide analog	59
Tumor necrosis factor blocker	542

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Vitamin D deficiency, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Vitamin D deficiency
Age	Reports	Share
Under 2	18	0.2%
2 to 11	93	1%
12 to 17	113	1.2%
18 to 44	1,609	16.7%
45 to 64	2,883	30%
65 to 74	866	9%
75 and over	475	4.9%
Age not given	3,561	37%

Sex of the patient in the reports that record Vitamin D deficiency
Sex	Reports	Share
Female	6,066	63.1%
Male	2,851	29.6%
Unknown or not given	701	7.3%

Age and sex are as the report gives them. 72.2% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Vitamin D deficiency: adverse event reports that record this term. https://reportedreactions.com/reaction/vitamin-d-deficiency/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Vitamin D deficiency mean in an adverse event report?

In plain words: low vitamin D. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page